Clinical Trial

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Study acronym: CASCADE
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-06-18; most recent amendment 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT05922124
Lead Sponsor Rambam Health Care Campus
Collaborators: Monaldi Hospital, Rutgers Robert Wood Johnson Medical School, Pisa University Hospital, Assaf-Harofeh Medical Center, Sheba Medical Center
Conditions Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
Enrollment 734 participants
Start Date 2024-09-01
Primary Completion 2026-07 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-01